Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States.
| Revenue (Most Recent Fiscal Year) | $631.45M |
| Net Income (Most Recent Fiscal Year) | $69.19M |
| PE Ratio (Current Year Earnings Estimate) | 6.24 |
| PE Ratio (Trailing 12 Months) | 6.68 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.73 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 3.14 |
| Pre-Tax Margin (Trailing 12 Months) | 7.50% |
| Net Margin (Trailing 12 Months) | 5.13% |
| Return on Equity (Trailing 12 Months) | 97.28% |
| Return on Assets (Trailing 12 Months) | 13.87% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.10 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 3.27 |
| Inventory Turnover (Trailing 12 Months) | 8.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.47 |
| Earnings per Share (Most Recent Fiscal Year) | $5.86 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.04 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 31.50M |
| Free Float | 30.71M |
| Market Capitalization | $1.22B |
| Average Volume (Last 20 Days) | 0.44M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.51% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |